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Circulating vitamin E, transforming growth factor b1, and the
association with renal disease susceptibility in two racial groups
with type 2 diabetes.
Background. End-stage renal disease caused by diabetes dis-
proportionately affects patients of African origin. The biologi-
cal mechanism(s) for this observation is unclear. Emerging data
from cross-sectional studies suggest that increased oxidative
stress and the cytokine, transforming growth factor b 1, are as-
sociated with this phenomenon. Therefore, a pathway involving
these factors could alter the vulnerability to renal disease and
impact adversely on the rate of loss of renal function.
Methods. We assessed the relationship between renal func-
tion, oxidative stress, and transforming growth factor b 1 in
58 patients with type 2 diabetes of African and Caucasian ori-
gin over 174 patient-years of follow-up. Oxidative stress was
assessed by measuring plasma lipid hydroperoxide and vita-
min E in the postprandial state. Creatinine clearance was cal-
culated from the Cockcroft-Gault equation. Patients received
standardized management of hypertension, hyperglycemia, and
hypercholesterolemia. Data were adjusted by multiple regres-
sion analysis to account for potential confounders.
Results. Lipid hydroperoxide was higher and vitamin E lower,
while there was no difference in fasting transforming growth fac-
tor b 1 between the African (N = 22) and Caucasian (N = 36)
patients [5.1(1.2) vs. 4.3 (1.8) lmol/L; P = 0.02 and 29.8 (10.8) vs.
41.3(19.7) lmol/L; P = 0.02 and 6.33 (5.5) vs. 6.84 (3.9) ng/mL;
P = 0.73], respectively. The mean (95% confidence interval)
of the difference in creatinine clearance between the patients
of African and Caucasian origin was −12.5 (−23.4 to −1.7)
mL/min; P =0.015 at baseline, the magnitude of which increased
to −17.5 (−28.4 to −6.5) mL/min; P = 0.002 after 3 years. The
fall in creatinine clearance from baseline among the patients of
African origin was greater for lower levels of vitamin E (rho =
0.48; P = 0.03). Final plasma creatinine was significantly higher
in the African patients compared with the Caucasian patients
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[109.0 (25.8) vs. 94.0 (20.0) lmol/L; P = 0.0017]. In regression
analysis, vitamin E was a significant and independent predictor
of plasma creatinine (t –3.17, P = 0.003).
Conclusion. In these patients with type 2 diabetes, vitamin E
is a determinant of renal function, and may explain some of the
racial differences in renal disease susceptibility that precedes
the divergence in incidence of end-stage renal disease.
The incidence of end-stage renal disease (ESRD)
due to diabetes mellitus is 4 times greater in patients
of African origin compared with white, Caucasian pa-
tients [1, 2]. This difference is not accounted for by the
higher prevalence of hypertension and diabetes in peo-
ple of African origin. Reports of the phenotypic differ-
ences between nonwhite and Caucasian patients with
diabetes suggest that renal complications occur earlier
and progress more rapidly in the former group [3, 4]. In
addition, these observations imply that the proven effec-
tiveness of antihypertensive therapy in slowing the re-
duction of creatinine clearance may vary between these
groups. The biological explanations accounting for these
differences remain unclear.
An increasing body of experimental evidence has im-
plicated reactive oxygen species, and an increase in oxida-
tive stress in the development of diabetic renal disease.
In rodent models, it has been shown that lipid peroxida-
tion products accumulate within the kidney [5]. More-
over, the process of lipid peroxidation, which, in part, is
regulated by vitamin E, features early in the development
of renal disease [6, 7]. A pathogenetic role for oxidative
stress is supported by studies showing that antioxidant
therapy in the form of vitamin E prevents glomerular
dysfunction and the histologic changes of kidney damage
[8, 9].
Accumulation of extracellular matrix in the glomeru-
lus is the hallmark of diabetic nephropathy. In cultured
human mesangial cells, the generation of peroxide in-
duces transforming growth factor-b 1 (TGF-b 1), which
increases extracellular matrix gene expression [10].
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Evidence is accumulating that a pathway involving in-
creased TGF-b 1 production may be relevant to the de-
velopment of renal disease in patients of African origin.
Up-regulation of TGF-b 1 production has been reported
to occur in patients of African origin compared with
Caucasians with established renal failure [11]. Of in-
terest, we found that patients without renal failure of
African origin had higher plasma lipid hydroperoxide
levels compared with Caucasians [12]. Together, these
observations suggest that increased oxidative stress asso-
ciated with alterations in TGF-b 1 and vitamin E could
be involved in the differences in racial vulnerability to
renal disease. It remains unknown if these variables are
relevant to measures of renal function in patients with
type 2 diabetes receiving therapy to preserve renal func-
tion. In this study, we measured vitamin E and TGF-b 1 in
patients of African and Caucasian origin with type 2 di-
abetes with preserved renal function who were prospec-
tively reviewed after 3 years follow-up.
METHODS
Patients
We studied 58 patients of African and Caucasian
origin with type 2 diabetes without a history of car-
diovascular disease. Both parents of patients of black,
African-Caribbean origin were native to either African
or Caribbean countries. White patients were confirmed
as being Caucasian if both parents originated from either
Western European or Mediterranean countries. A diag-
nosis of type 2 diabetes was based on an absence of ketosis
at, or need for insulin within 1 year of diagnosis. Patients
with malignancy were excluded. Diabetic retinopathy
was screened for using direct ophthalmoscopy and
recorded as present (background, preproliferative, or
proliferative) or absent.
The number (%) of patients treated with diet
alone/oral hypoglycemic agents/insulin alone or a com-
bination of insulin and oral hypoglycemic agents was
5 (9)/28 (49)/19 (33) or 5 (9), respectively, and 22 (38%)
of the patients had evidence of retinopathy. Those who
were current smokers or had previously smoked were
classified as having a positive smoking history.
All patients received standardized treatment and were
reviewed on a 6-month basis. Management was modi-
fied to try and achieve an optimal glycated haemoglobin
(HbA1c) of ≤7%, sitting blood pressure of <130/80 mm
Hg, and total cholesterol of <5 mmol/L. First-line antihy-
pertensive therapy was either an angiotensin-converting
enzyme inhibitor (ACEI) or angiotensin II receptor
blocking (ARB) agent. These agents were titrated up
to their maximal limit before adding in a thiazide di-
uretic and, thereafter, additional agents, depending on
the blood pressure response.
Clinical and biochemical parameter measurement
Blood pressure was measured after 10 minutes rest us-
ing a digital oscillometric sphygmomanometer (Omron
HEP705 CEP; Tokyo, Japan) with the mean systolic and
diastolic reading calculated from 3 recordings. Body mass
index (BMI) was calculated from weight in kilograms di-
vided by height in meters squared.
A sample of venous blood (30 mL) was collected
into EDTA after an overnight fast. Plasma was as-
pirated and stored at −70◦C for subsequent analysis.
Total cholesterol, HDL-cholesterol, and triglycerides
were estimated using enzymatic methods (Boehringer-
Manheim, Mannheim, Germany). HbA1c was measured
by high-performance liquid chromatography (HPLC)
(Menarini 8140; Wokingham, UK). Urinary albumin and
creatinine were measured by immunoturbidity (Cobas
Fara, Roche Diagnostics, Lewes, UK) and the Jaffe rate
reaction methods, respectively. Creatinine clearance was
calculated according to the Cockcroft and Gault formula
and corrected for a body surface area of 1.73m2 [13].
Plasma lipid hydroperoxide measurement
Plasma lipid hydroperoxide was measured as previ-
ously described [14]. Briefly, 90 lL aliquots of plasma
were transferred into 2 pairs of vials, and methanol
and triphenylphosphine (TPP) added to one or other
pair. Then 900 lL of FOX2 reagent [xylenol orange
(100 lmol/L), BHT (25 mmol/L) and ferrous sulfate
(250 lmol/L) in methanol (90%, V/V)] was added to
the vortexed samples. After centrifugation at 12,000g for
5 minutes, the samples were read spectrophotometeri-
cally at an absorbance of 560 nm. The content of plasma
lipid hydroperoxide was determined as a function of the
mean absorbance difference between samples with and
without TPP. The intraindividual coefficient of variation
was <5%.
Vitamin E measurement
Aliquots of plasma sample (100 lL) were placed in
glass tubes. One hundred ng c-tocopherol in 500 lL of
ethanol was added as internal standard, and the sample
was vortex mixed. Five hundred lL of water and 1 mL of
n-hexane were added, and the samples were centrifuged
for 5 minutes at 1500g. The upper (hexane) layer was as-
pirated and transferred to a small glass vial. The lipid ex-
traction procedure was repeated by adding another 1 mL
of hexane, and the pooled layers were evaporated to dry-
ness under a stream of nitrogen. The residue was dis-
solved into 100 lL of acetonitrile, and 20 lL was then
injected on to the HPLC column. The analysis was car-
ried out on an HPLC system and flouorimeter (Gilson,
Anachem, Scotland, UK). The column was eluted with
acetonitrile/water (80/20, V/V), and the eluent monitored
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using a fluorometric detector; the excitation wavelength
was 295 nm and the emission wavelength was 340 nm [15].
The intraindividual coefficient of variation was <6.5%.
Plasma TGF-b1 measurement
Total TGF-b 1 was determined by enzyme-linked
immunosorbent assay (ELISA) (Biotrak, Amersham
Biosciences, Buckinghamshire, UK). Briefly, 200 lL of
plasma were combined with 200 lL acetic acid (2.5 mol/L)
for 10 minutes at room temperature. The sample was
neutralized by adding 200 lL of NaOH (2.7 mol/L). The
sample was then diluted by adding assay buffer (3 mL).
Aliquots (100 lL) of the samples were plated on an
anti-TGF-b 1–coated microtitre plate and incubated at
37◦C for 1 hour. The plate was washed with phosphate
buffer and incubated with biotin-conjugated anti-TGF-
b 1 (0.5 lL/assay), washed again, and then 100 lL of
diluted streptavidin-horseradish peroxidase (HRP) con-
jugate added. After incubation, 100 lL of TMB substrate
(tetramethylbenzidine/hydrogen peroxide, in 20% (V/V)
dimethylformamide) was added followed by 100 lL of
sulphuric acid (0.19 mol/L) to terminate the reaction, af-
ter which the plate was read at 450 nm. The upper limit
of the range and sensitivity of the assay was 1000 pg/mL
and <4 pg/mL, respectively.
Statistics
Data were computed using SPSS 10.1 (SPSS, Chicago,
IL, USA) for Windows with parametric or nonparamet-
ric tests according to their distribution. Urinary albumin
excretion rate and triglycerides were log transformed
prior to analysis. Multiple regression analysis was used
to adjust the associations between change in creatinine
in relation to racial origin, age, systolic blood pressure,
fasting glucose, and a-tocopherol. The study had 90%
power to detect a 15 lmol/L difference in final plasma
creatinine at P < 0.05. One-way analysis of variance
(ANOVA) with Bonferroni correction was applied for
multiple comparisons. Results are presented as mean
(standard deviation), all tests were two-tailed, and a P
value of < 0.05 was accepted as statistically significant
unless otherwise stated.
RESULTS
The demographic, clinical, and biochemical character-
istics of the groups at baseline are shown in Table 1. The
groups were similar with respect to age and sex distribu-
tion, and received similar treatment regimens for hyper-
tension and glycemic control. Caucasian patients were
nearly twice as likely as African patients to have a pos-
itive smoking history. The group of African origin had
significantly higher diastolic blood pressure and HDL-
cholesterol but lower triglycerides. Creatinine clearance
Table 1. Baseline clinical and biochemical characteristics of patients
with type 2 diabetes of African and Caucasian origin
Variable African Caucasian P
Number 22 36 –
Male% 46 63 0.20
Age years 62.1 (7.8) 57.2 (10.7) 0.07
Duration of diabetes
years
12.0 (8.9) 10.0 (9.3) 0.43
Number with
retinopathy%
9 (16) 13 (22) 1.00
Percentage with
smoking history
36 61 0.14
Treatment for
glycemic control
Diet/OHA/insulin/
OHA+insulin
2/10/8/2 3/18/11/3 0.9
Number receiving
ACE/ARB%
11 (50) 19 (53) 0.65
BMI kg/m2 28.6 (2.8) 30.0 (6.2) 0.31
Systolic blood
pressure mm Hg
161.9 (17.0) 145.5 (23.7) 0.08
Diastolic blood
pressure mm Hg
88.1 (10.1) 80.4 (11.3) 0.01
Fasting glucose
mmol/L
9.7 (4.3) 10.7 (3.3) 0.33
HB A1c% 8.0 (1.2) 7.3 (1.5) 0.08
Total cholesterol
mmol/L
5.3 (0.7) 5.4 (1.1) 0.68
HDL-cholesterol
mmol/L
1.7 (0.4) 1.3 (0.5) 0.008
Triglycerides
mmol/L
1.2 (0.5) 1.9 (1.2) 0.006
Plasma creatinine
lmol/L
107.3 (16.2) 97.1 (19.2) 0.07
Creatinine clearance
mL/min/1.73m2
70.0 (40.9) 86.1(25.5) 0.01
TGF-b 1 ng/mL 6.33 (5.5) 6.84 (3.9) 0.73
Urinary albumin
excretion mg/daya
63.4 (11.0–133.7) 39.8 (22.4–89.0) 1.00
Abbreviations are: OHA, oral hypoglycemic agents; ACE, angiotensin-
converting enzyme inhibitor; ARB, angiotensin II receptor blocker; TGF-b 1,
transforming growth factor-b 1.
a Median (interquartile range).
was significantly higher in the Caucasian patients. Plasma
lipid hydroperoxide levels were higher and vitamin E lev-
els lower in patients of African origin (Fig. 1).
Effect of treatment on blood pressure, glycemic control,
and lipids
After 3 years’ follow-up, there were no differences in
the proportion of the African and Caucasian groups re-
ceiving diet alone/oral agents/insulin alone or oral agents
and insulin for their glycemic control (4.5/45.5/41.0/9.0%
and 9.1/42.4/42.4/6.0; P = 0.90). The proportion of pa-
tients on ACE/ARB-based antihypertensive treatment
in the African and Caucasian groups after 3 years was
35% and 57%, respectively (P = 0.04). Systolic blood
pressure was similar, diastolic blood pressure lower [152.5
(17.2) vs. 144.3 (21.0); P = 0.16 mm Hg, and 86.5 (10.1) vs.
79.3 (11.1) mm Hg; P = 0.008], and the mean fall in total
cholesterol was 0.47 mmol/L (P = 0.004) and 0.58 mmol/L
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Fig. 1. Concentrations of fasting lipid hydroperoxide (solid bars) and
vitamin E (stippled bars) in patients with type 2 diabetes of African and
Caucasian origin.
(P = 0.004) in the African and Caucasian groups, respec-
tively. There were no differences between the groups in
urinary albumin excretion, fasting glucose, glycosylated
hemoglobin, or triglycerides.
Changes in renal function after 3 years of follow-up
Patients of African origin had a lower baseline crea-
tinine clearance (Table 1). The mean (95% CI) of the
difference in creatinine clearance between the patients
of African and Caucasian origin was −12.5 (−23.4 to
−1.7) mL/min, P = 0.015 at baseline, the magnitude of
which increased to −17.5 (−28.4 to −6.5) mL/min, P =
0.002. Final (and baseline) creatinine clearance corre-
lated with vitamin E in the African group (rho = 0.60;
P = 0.005). The percentage change in creatinine clear-
ance from baseline among the patients of African origin
correlated with vitamin E concentrations (rho = 0.48; P =
0.03). The greater the fall in clearance, the lower was the
baseline level of vitamin E (Fig. 2).
For the whole cohort, patients in the lowest quartile
of the vitamin E distribution had significantly higher fi-
nal plasma creatinine than those in the highest quartile
(Fig. 3). Baseline and final plasma creatinine correlated
inversely with vitamin E (rho = −0.35; P = 0.007, and
rho = −0.44; P = 0.001, respectively). In the African
group, final plasma creatinine was significantly higher
[109.0 (25.8) vs. 94.3 (20.0) lmol/L; P = 0.017] when com-
pared with the Caucasian group. With final plasma creati-
nine as the dependent variable in multiple regression, age,
and vitamin E were independent predictors. Racial ori-
gin was not an independent predictor in this model. The
standardized b coefficients suggested that plasma creati-
nine would rise by 0.43 lmol/L for every lmol/L fall in
vitamin E (Table 2).
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Fig. 2. Relationship between the percentage of change in creatinine
clearance after 3 years of follow-up relative to baseline values of vitamin
E in patients of African origin with type 2 diabetes.
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Fig. 3. Relationship of the lowest to the highest (Q1 to Q4) quartiles
of vitamin E measured at baseline to the plasma creatinine measured
after 3 years’ follow-up in all patients with type 2 diabetes.
Table 2. Multiple regression analysis with plasma creatinine after
3 years’ follow-up as the dependent variable
Variable Standardized b t P
Age years 0.398 1.91 0.032
Vitamin E lmol/L −0.433 −3.17 0.003
African origin 0.045 0.318 0.752
Systolic blood pressure mm Hg 0.121 0.846 0.402
Fasting plasma glucose mmol/L 0.143 0.924 0.361
DISCUSSION
Our study has found vitamin E to be a predictor of re-
nal function in patients with type 2 diabetes. The lower
levels found in patients of Africa origin were associated
with a faster decline in creatinine clearance from base-
line values after 3 years of follow-up. These relationships
support the hypothesis that low vitamin E status could
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be an adverse risk factor for the vulnerability and pro-
gression of diabetic renal disease. Moreover, these find-
ings provide insight into the biological mechanisms that
might contribute to the differential incidence of ESRD
between patients of African and Caucasian origin.
Vitamin E is a scavenger of free radicals, and has an
important role in the defense against oxidative stress. It
maintains concentrations of reduced glutathione, and the
activities of the antioxidant enzymes, superoxide dismu-
tase, catalase, and glutathione peroxidase in the glomeruli
[16–18]. Craven et al reported that biochemical markers
and histologic features of diabetic nephropathy were at-
tenuated in streptozotocin rats that received dietary sup-
plementation of vitamin E [19]. In this model, dietary
supplementation increased vitamin E concentrations in
the renal cortex, and was associated concomitantly with
a reduction in glomerular expansion and content of
TGF-b 1.
TGF-b 1 facilitates the assembly and reduces the degra-
dation of extracellular matrix proteins [20]. It has numer-
ous actions, in part mediated through other cytokines,
such as fibroblast growth factor, endothelin-1, and plas-
minogen activator inhibitor-1 [21]. It is implicated in a
number of chronic diseases that are associated with organ
fibrosis, including hypertension, left ventricular hypertro-
phy, and ESRD. An increase in immunoreactive TGF-b 1
has been reported in the kidneys of animal models and hu-
mans with diabetic nephropathy [22]. Furthermore, treat-
ment with monoclonal antibodies to TGF-b 1 in the db/db
mouse model is associated with a reduction in glomeru-
lar expansion, the histologic hallmark of early diabetic
nephropathy [23]. Consequently, the regulation of TGF-
b 1 is regarded as an important candidate to explain the
increased susceptibility to ESRD. Higher TGF-b 1 pro-
tein has been reported in African Americans with ESRD
[24]. Support for this observation being a race-dependent
phenomenon has come from work showing that expres-
sion of TGF-b 1 was higher in black, nondiabetic subjects
with and without hypertension and normal renal function
[11]. We studied patients with type 2 diabetes and normal
renal function, but we did not find racial differences in
circulating TGF-b 1. There were no differences between
the groups in the use of thiazolidinediones, which may
have had an effect on TGF-b 1 concentrations and renal
function [25]. Renal function was more impaired in pa-
tients of African origin in our study at baseline, but it is
not clear at what stage in the progression to ESRD that
differences in circulating TGF-b 1 become apparent, and
our study may have been insufficiently powered to detect
small differences.
The differences in renal function between the racial
groups persisted after correcting for age, systolic blood
pressure, and glycemic control. Adjusting for diastolic
blood pressure, which was lower in the Caucasian pa-
tients, instead of systolic pressure did not alter the out-
comes (data not shown). Treatment that significantly low-
ered systolic blood pressure and total cholesterol in the
patients of African origin was not associated with a re-
duction in the rate of loss of function over 3 years. This
observation could be related to stabilization of the de-
cline in creatinine clearance in the Caucasian patients,
as well as accelerated loss in the patients of African ori-
gin. Consistent with our finding is a study of 58 patients
prescribed ACEI and/or ARB therapy in which creati-
nine clearance fell significantly in those randomized to
placebo compared with those treated for 12 months with
the lipid-lowering drug atorvastatin [26]. Of further note,
not all African Americans with hypertensive renal dis-
ease who achieved lower blood pressures in the AASK
trial benefited, with a slower disease progression com-
pared to those with higher blood pressures [27]. Our pa-
tients received treatment strategies based on the findings
from studies largely undertaken in white populations [28–
30]. Together, these data suggest that the effect of con-
ventional treatment is inconsistent, and may be limited
or unable to address elements of the disease process in
some groups of patients.
The benefit of vitamin E supplementation on cardio-
vascular disease for patients at risk of, or with ESRD, has
been conflicting [31–33]. However, recent studies have
shown that vitamin E supplementation is able to abro-
gate specific hemodynamic and biochemical abnormal-
ities associated with renal disease in man [34, 35]. It is
of note in these studies that supplementation achieved
concentrations of vitamin E which were similar to those
in the Caucasian group in our study. We have previously
reported that patients with type 2 diabetes of African ori-
gin with microalbuminuria have reduced renal vascular
reserve compared with matched Caucasian patients [4].
This defect in vascular function was associated with a re-
duction in the excretion of nitric oxide metabolites. A po-
tential explanation for this association is that nitric oxide
bioavailability was reduced by reactive oxygen species.
This could be one mechanism by which an increase in ox-
idative stress, through a reduction in vitamin E, increases
the vulnerability to renal disease in patients of African
origin. Population-based studies support this hypothe-
sis. People of African origin have been found to have
lower concentrations of vitamin E compared with Cau-
casians [36]. Furthermore, as we have demonstrated with
vitamin E, persons with lower concentrations of lipid-
soluble antioxidant vitamins have a higher risk of renal
disease [37]. These observations suggest that modifiable
components of the reduction/oxidation (redox) pathway
might contribute to renal disease susceptibility. Vitamin
E may therefore modulate the hemodynamic aspects of
renoprotective therapy, and is of relevance before the
divergence in incidence of ESRD between (and possi-
bly within) these groups. An intervention study involv-
ing these racial subgroups with diabetes is warranted to
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demonstrate the impact of altering redox balance on re-
nal disease in the longer term.
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